Drug details

Qternmet XR (dapagliflozin, saxagliptin, and metformin hydrochloride)

type of Antidiabetics, SGLT2 Inhibitors

Qternmet XR (dapagliflozin, saxagliptin, and metformin hydrochloride) is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and a biguanide combination product indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. 

The following drugs are related to Qternmet XR, either as a replacement or used together:

• Tanzeum (albiglutide pen for injection, for subcutaneous use)
• Kazano (alogliptin and metformin hcl tablets)
• Oseni (alogliptin and pioglitazone tablets)
• Nesina (alogliptin tablets)
• Parlodel (bromocriptine mesylate)
• Bydureon (exenatide)
• Bydureon Bcise (exenatide extended-release injectable suspension)
• Invokamet XR (canagliflozin and metformin hydrochloride)
• Invokamet (canagliflozin and metformin hydrochloride tablets)
• Farxiga (dapagliflozin film-coated tablets)
• Trulicity (dulaglutide injection, for subcutaneous use)
• Glumetza (metformin hcl)
• Tresiba (insulin degludec injection)
• Januvia (sitagliptin phosphate)
• Onglyza (saxagliptin tablets)
• Ozempic (semaglutide injection)